Get this delivered to your inbox, and more info about our products and services.
Buy this best-in-class GLP-1 leader as competition heats up, says Barclays
Barclays' $1,350 price target implies upside of 32%.
14 words~1 min read
Related reading
This new GLP-1 play is on a tear. UBS sees nearly a 50% gain from here
MBX Biosciences has rallied more than 230% over the past year, but there's room for still more upside from current levels,…
We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge…
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing…
This pharmaceutical stock is cheap relative to peers. UBS thinks it's due for a…
The investment bank upgraded the pharmaceutical name to buy from neutral.
Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli…
Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.
Why Eli Lilly will win the GLP-1 race – plus, a promising sign for Boeing…
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
This biotech firm has room to run despite surging nearly 500% in past year,…
The investment bank upgraded the pharma stock to overweight from equal weight.